INTRODUCTION
Bleeding from esophagogastric varices (EGVs) is one of the most common causes of death among patients with portal hypertension. The successful diagnosis and management of EGVs can significantly improve the outcomes for such patients. There are several types of endoscopic treatment for EGVs, such as endoscopic injection sclerotherapy (EIS), endoscopic variceal ligation (EVL), or cyanoacrylate glue (CYA) injection under conventional endoscopy. However, these approaches are performed blindly because the exact location of the varix under or outside the wall of the esophagus and stomach cannot be observed directly.
Recently, endoscopic ultrasound (EUS) has provided advantages in the diagnosis and management of EGVs. The largest advantage of EUS is that it allows endoscopists to observe the varix lumen directly under or outside the wall of the esophagus and stomach. In this review, we aimed to highlight the utility of EUS in the diagnosis and management of EGVs. Articles for this review were selected from a PubMed review of English-language articles. Furthermore, references were reviewed to retrieve additional articles related to this field.
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GRADING OF ESOPHAGOGASTRIC VARICES

Grading of esophageal varices
Grading of esophageal varices (EVs) by endoscopy is subjective. At present, there are three grading systems, including those put forth by Dagradi, [1] the Japanese Research Society for Portal Hypertension (JRSPH), [2] and the North Italian Endoscopy Club for the Study and Treatment of EVs (NIEC). [3] In 1972, Dagradi classified EVs into five Grades: I: EVs measuring 1-2 mm in diameter with a straight or sigmoid shape; II: EVs similar to Grade I but visible without occluding blood flow in the vessel; III: EVs 3-4 mm in diameter and straight or tortuous; IV: EVs 4-5 mm in diameter, tortuous, often coiled, and observed in all quadrants of the esophagus; and V: EVs larger than 5 mm in diameter, tightly packed, grape-like, and covered by thin, wrinkled mucosa with overlying cherry-red spots and telangiectasias. In 1980, the JRSPH system classified varices according to location, form, color, and the red color sign as follows: (1) The location of the varices may be the upper, middle, or lower third of the esophagus or upper stomach; (2) the form of the varices is classified as small and straight (F1), enlarged and tortuous (F2), or large and coil-shaped (F3); (3) the color of the varices is graded as white (Cw) or blue (Cb); (4) the red color sign is present in cases with dilated, small vessels (red wale sign), and telangiectasias or cherry-red spots on the surface of the varices. In 1988, the NIEC index-graded EVs based on the following factors: (1) The Child-Pugh Class of Cirrhosis (A, B, or C), (2) variceal size (small, medium, or large), and (3) the presence of red color signs (absent, mild, moderate, or severe).
Grading of gastric varices
Gastric varices (GVs) are generally classified using Sarin's classification [4, 5] based on the location and direction of blood flow. Gastroesophageal varices 1 (GOV1) is the most common type and accounts for 74% of all GVs; this type consists of EVs extending along the lesser curvature of the stomach. GOV2 is used to define EVs extending along the greater curvature near the fundus. IGV1 (isolated GVs) describes isolated GVs localized to the fundus, with no association with EVs; these GVs emerge from splenorenal or gastrorenal shunts, in which the feeding vessel emerges from the splenic hilum and drains into the left renal vein via the gastric cardia or fundus veins. IGV2 describes isolated GVs presenting elsewhere other than the fundus, which drains in a similar fashion into the left renal vein but with multiple tributaries. GOV2 and IGV1 account for 80% of all bleeding GV patients, although they are less prevalent than GOV1 varices. Another commonly used classification of GVs is based on the shape of the varices (tortuous = F1, nodular = F2, and tumorous = F3), their location (anterior = La, posterior = Lp, lesser curvature = Ll, greater curvature = Lg, the cardia, and fundic area = Lf) and their color (white = Cw or red = Cr). [6] 
VISUALIZATION AND EVALUATION OF ESOPHAGOGASTRIC VARICES
Visualization and evaluation of esophageal varices
EUS was found to be inferior to conventional endoscopy in detecting and grading EVs (14% in Grade 1, 50% in Grade 2, and 78% in Grade 3) but superior in the detection of periesophageal veins (57% in Grade 1, 89% in Grade 2, and 100% in Grade 3) and gastric fundal veins. Moreover, the detection of periesophageal veins with EUS increased with an increasing diameter of EVs at endoscopy. Similar observations were made in another study, suggesting the sensitivity of EUS may increase with higher endoscopic grade of EVs. [7] Visualization and evaluation of gastric varices A number of studies have confirmed the superiority of EUS over conventional endoscopy in the detection of GVs. [8] [9] [10] [11] [12] A recent study indicated that the GV diameter, which was independent from the variceal form, Child-Pugh Classification and the presence of hepatocellular carcinoma was closely related to the GV flow volume. [13] Visualization and evaluation of the portal vein, portosystemic shunt, and azygous vein Wiersema et al . [14] used duplex and color Doppler (CD) EUS to assess 20 asymptomatic volunteers and 11 patients with suspected splenic and/or portal thrombosis or a portosystemic shunt. In 10 of the 11 patients, duplex endosonography provided a correct diagnosis in 10/11 patients, while transabdominal ultrasound failed to provide a correct diagnosis in all of the patients. This finding indicated that patients with suspected splenic and/or portal thrombosis or a portosystemic shunt should undergo EUS when transabdominal ultrasound is nondiagnostic. Another study also compared the detection rate of curved linear array (CLA) EUS for gastrorenal shunts with that of contrast-enhanced computed tomography (CECT). These results showed that CLA echo-endoscopy could successfully identify a gastrorenal shunt and provide similar accuracy with CECT. [15] The diameter of the azygous vein using EUS at its distal and proximal margins was also significantly greater in patients with portal hypertension. Moreover, the study indicated the diameter also increased with the variceal grade. [8] 
PREDICTION OF BLEEDING AND EVALUATION OF THE TREATMENT RESPONSE
Prediction of bleeding
EUS can identify hematocystic spots on the surface of EVs, whose presence is closely associated with a high risk of esophageal variceal rupture. These appear as saccular aneurysms, similar to projections on the variceal surface as observed using high-resolution endoluminal sonography. [16] Moreover, paraesophageal and paragastric varices detected by EUS have been shown to correlate with the presence and severity of portal hypertension and may be a risk factor for variceal bleeding.
Several studies have classified these collaterals as large if they were >5 mm [17] or wider than the splenic vein. [18] Faigel studied 36 cirrhotic patients (31 with prior hemorrhage) and 32 control patients, and paraesophageal varices were detected in 97% of cirrhotic patients and 3% of control patients. In addition, the gastric mucosa and submucosa were thicker for cirrhotic compared to control patients, and paraesophageal varices (odds ratio [OR] 3.1) and paragastric varices (OR 3.7) were larger in hemorrhage patients. [19] A study by Miller et al. [20] showed that EUS could measure the severity of EVs by summing the cut surface area (CSA) using a digitized image. These authors demonstrated a 76-fold increase per year in the risk of variceal rebleeding for each 1 cm 2 increase in variceal CSA. Using a cutoff value of 0.45 cm 2 for the CSA, the sensitivity and specificity for future variceal bleeding above and below this value were 83% and 75%, respectively.
Evaluation of the endoscopic treatment response
One study used EUS to examine 38 patients who had undergone EIS. EUS found a significantly higher incidence of severe-type periesophageal collateral veins and significantly larger and more perforating veins in patients with endoscopic recurrences of EVs compared to patients without recurrence. [21] Another study used CD-EUS to study 306 patients in which EVs had been treated with EIS. These patients underwent CD-EUS before EIS and 3-5 months after EIS and the results showed that the predictors of early recurrence of EVs within 1 year included more perforating veins and the inflowing type of perforating veins before EIS and more cardiac intramural veins and perforating veins and the inflowing type of perforating veins after EIS. [22] EUS also enabled visualization of the left gastric vein (LGV). The branching pattern of the LGV was also found to be closely associated with the early recurrence of EVs as the dominance of the anterior branch may be responsible for directing LGV blood flow toward varices at the level of the proximal stomach. [23] Hepatofugal flow velocity was also shown to increase with varices of an increasing size. [24] Kuramochi et al. [25] included 68 patients treated for moderate or large EVs who underwent CD-EUS after EVL and sclerotherapy. Patients with a high hepatofugal flow velocity in the LGV (>12 cm/s) or an anterior branch dominant pattern were classified into a high-risk group. Half of the patients showed a recurrence of EVs within half a year, whereas it took nearly 2 years for half of the patients in the other group to exhibit a recurrence. The hazard ratio of these features for early recurrence was 3.0. Another study collected thirty consecutive patients with EVs at high risk for bleeding, and simultaneous conventional endoscopy and EUS were performed before endoscopic therapy. This study showed that EUS revealed cardial submucosal varices in all patients, while conventional endoscopy showed varices in 70% of patients. Furthermore, patients with recurrent EVs were more likely to have severe-grade perforating veins prior to treatment (71.4%) compared to patients without recurrence (12.5%), and patients with severe as opposed to mild-grade perforating veins before treatment had a significantly higher recurrence rate (90.9% vs. 21.0%). [10] Evaluation of the pharmaceutical and surgical treatment response With EUS, the azygos vein diameter as well as valuable quantitative and qualitative data, such as the blood flow volume index, can be obtained. [26] Azygos blood flow (AzBF) and diameter can serve as an index of blood flow via gastroesophageal collateral vessels and varices in portal hypertension. [26, 27] Lee et al. [28] studied the feasibility of assessing AzBF using CD-EUS and of monitoring the effects of vasoactive agents on AzBF, and these authors found that there was a marked decrease in AzBF after 1, 5, and 10 min bolus injections of terlipressin and somatostatin. However, the control group showed no significant change in AzBF. Liao et al. [29] used EUS to evaluate the volumetric change of paraesophageal varices in patients treated with propranolol who achieved EV eradication using primary EVL. These authors concluded that EUS is an objective and useful tool to measure PEV and to predict the recurrence of EV. Another study included 42 cirrhotic patients with EGV treated with devascularization surgery for variceal hemorrhage and demonstrated that combined percutaneous transhepatic portography and EUS was very helpful in determining the adequate modalities of devascularization surgery. [30] 
ASSISTANCE IN ENDOSCOPIC THERAPY
Assistance in endoscopic therapy on esophageal varices
The injection of sclerosant has been generally performed under conventional endoscopy to treat EV. The injection is "blind" and may be paravariceal. Delivery of sclerosant under EUS guidance through a standard fine-needle aspiration (FNA) needle has the advantage of enabling real-time confirmation of delivery into the varix lumen. EUS can display the main "perforator" feeding vein. Targeting the perforating vessel rather than the varix lumen reduced the amount of sclerosant needed to achieve obliteration of varices and reduced the risk of rebleeding and complication. It may also decrease the recurrence rate of EVs after initial obliteration. [31] A randomized controlled trial compared the efficacy of EIS and EUS-guided sclerotherapy of esophageal collateral veins. The results showed that the recurrence of EVs was less frequent and occurred later, although a significant difference was not achieved [ Figure 1 ]. [32] However, this trial has some limitations, such as one-center experience and small sample size. This conclusion needs to be confirmed in more multicenter trials with large sample size. Only after proving the superiority of EUS over conventional endoscopy, we could recommend routine use of EUS for treating EGVs.
Assistance in endoscopic therapy on gastric varices
It is known that delivery of CYA under EUS guidance has the advantage of enabling precise delivery of the glue into the varix lumen. EUS also enables an assessment using Doppler to confirm vessel obliteration after treatment. However, targeting the perforating feeder vessel rather than the varix lumen itself may theoretically minimize the amount of CYA needed to achieve obliteration of GVs and thereby reduce the risk of embolization. Romero-Castro et al. [33] assessed the efficacy of EUS-guided CYA injection at the entrance of the perforating veins to obtain variceal obturation in five consecutive GV patients. These patients successfully underwent the procedure without recurrent bleeding or other complications during the study follow-up period. However, one limitation of this approach is that identification of the perforating vessel with EUS can be difficult and time-consuming. Liao et al. [34] used a miniature ultrasound probe (MUP) to evaluate the adequacy of tissue adhesive obturation of GVs in patients with bleeding. These authors demonstrated that MUP could evaluate inadequate obturation of GVs and guide the reinjection of CYA, which may reduce the probability of rebleeding. A multicenter study retrospectively compared the feasibility, safety, and application of CYA injection and EUS-guided coil application (ECA) embolization of feeding GVs. [35] Thirty consecutive patients with localized GVs in tertiary medical centers received either CYA injection (19 patients) or ECA (11 patients) and they were followed up to 6 months after treatment. The results showed no significant difference in the GV obliteration rate between the two groups (94.7% in CYA vs. 90.9% in ECA). However, adverse events occurred much more frequently in the CYA group (57.9%) compared to the ECA group (9.1%), although no patients died from causes related to the procedures or bleeding. This study also revealed that ECA required fewer endoscopies and tended to have fewer adverse events compared with CYA injection in treating localized GVs. Another study reported a fistula-like communication between the gastric wall and paragastric collateral vessels suspected by EUS in a patient after CYA injection for GV bleeding. [36] Conventional endoscopic examination showed no active bleeding, and only a small ulcer-like mucosal depression over the previous CYA injection site was ever found. EUS-guided CYA injection into the paragastric collateral vessels, and the amount of CYA required for obliteration of the injected vessel was also determined under EUS.
Assistance in endoscopic transesophageal therapy on gastric varices
The gastric fundus is well visualized on EUS with the transducer positioned in the distal esophagus. In addition to enabling EUS-guided access to the GFV, the transesophageal approach is not hindered by gastric contents, such as blood and food. There is also no disruption of the gastric mucosa overlying the varix. One study assessed the feasibility, safety, and efficacy of transesophageal EUS-guided therapy of GFV with combined coil and CYA injection. [37] These investigators enrolled thirty patients with gastric fundal varices between 2009 and 2011, and these patients successfully underwent EUS-guided transesophageal treatment of GFV. Their results demonstrated that the mean number of treatments was 1.3 per patient, and the mean volume of CYA was 1.4 mL per varix. Hemostasis of acute bleeding was achieved in all patients, and GFVs were obliterated after a single treatment session in 96% of patients. Rebleeding occurred in only 16.6% of patients, and none of the cases of rebleeding was due to GFV. Furthermore, no procedure-related complications were found. However, this was a pilot study at a single center, and the safety and efficacy of this novel technique warrant further investigation [ Figures 2 and 3] .
Assistance in endoscopic intrahepatic portosystemic shunt
The ability to access the portal vein via the stomach or duodenum may provide potential future therapeutic use, such as the direct placement of an EUS-guided intrahepatic portosystemic shunt (IPSS). Buscaglia et al. [38] studied the feasibility of EUS-guided IPSS creation in a live porcine model. Under linear-array EUS guidance, these authors punctured the hepatic vein and subsequently the portal vein using a 19-gauge FNA needle, and a metal stent was deployed under EUS and fluoroscopic guidance. The distal end of the stent was positioned inside the portal vein, and the proximal end was within the hepatic vein [ Figure 4 ]. There was no evidence of bleeding or damage to any intraperitoneal organs after the entire procedure. There were also no complications during the follow-up period over the next 2 weeks. Taken together, these data suggest that EUS-guided creation of an IPSS might become a useful alternative to conventional transjugular intrahepatic portosystemic stent-shunt.
CONCLUSION
EUS plays an important role in the diagnosis and management of EGVs [ Table 1 ]. Indeed, its use in EGVs and portal hypertension has expanded with the increasing availability of this instrument worldwide and has improved our understanding and training in endosonography. However, EUS-guided therapy has some concerns as well. Few single-centered randomized trials with small sample size have proved the superiority of EUS-guided approach over conventional endoscopic one. As EUS-guided therapy of EGVs is more expensive for patients and more experience-demanding for endoscopists than conventional endoscopy approach, the cost benefit of the EUS-guided treatment of varices has to be considered as well. With regards to the injection for the treatment of EV and GV, there is currently no consensus on the location of injection, number of injections in each session, type of agents, and volume of each injection, which have an influence on the efficacy and safety of the procedure. There are large variations in these aspects among procedures by different endoscopists due to their technical level and experiences. However, we believe that the use of EUS in the diagnosis and therapy of EGVs is expanding and will continue to play a more significant role in this field in the future. 
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